NCT05712083

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Detailed description

This is a single arm, open-label, single-center study. This study is indicated for newly diagnosed multiple myeloma. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 40 patients will be enrolled. Primary objective is to explore the safety and efficacy

Conditions

• Multiple Myeloma
• New Diagnosis Tumor

Interventions

Type	Name	Description
DRUG	BCMA CAR-T cells	Each subject receive BCMA CAR T-cells by intravenous infusion

Timeline

• Start date: 2023-01-30
• Primary completion: 2024-04-01
• Completion: 2024-04-01
• First posted: 2023-02-03
• Last updated: 2023-02-21

Locations

1 site across 1 country: China